53927-12-1

Basic information

• Product Name: Ethyl trans-3-(1-pyrrolidino)acrylate
• Synonyms: Ethyl b-(1-Pyrrolidinyl)acrylate;1-Pyrrolidineacrylic acid ethyl ester
• CAS NO: 53927-12-1
• Molecular Formula: C₉H₁₅NO₂
• Molecular Weight: 169.2209
• Mol File: 53927-12-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 245.9°C at 760 mmHg
• Flash Point: 95.9°C
• Appearance: /
• Density: 1.112g/cm³
• Vapor Pressure: 0.028mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: Ethyl trans-3-(1-pyrrolidino)acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl trans-3-(1-pyrrolidino)acrylate(53927-12-1)
• EPA Substance Registry System: Ethyl trans-3-(1-pyrrolidino)acrylate(53927-12-1)

Safety Data

• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36:Wear suitable prot
• Hazardous Substances Data: 53927-12-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H15NO2/c1-2-12-9(11)5-8-10-6-3-4-7-10/h5,8H,2-4,6-7H2,1H3/b8-5+

Upstream product

• 123-75-1 pyrrolidine 
• 623-47-2 propynoic acid ethyl ester 

Downstream Products

• 63969-84-6 ethyl 2-formyl-phenyl-acetate 
• 57988-74-6 N²-tosyl-N¹,N¹-cyclobutylformamide 
• 1224944-85-7 3-o-tolyl-isoxazole-4-carboxylic acid ethyl ester 
• 176969-34-9 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid 
• 1204298-65-6 5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid 
• 639523-11-8 3-ethyl-isoxazole-4-carboxylic acid ethyl ester 
• 20328-15-8 3-methylisoxazole-4-carboxylic acid ethyl ester 

Relevant articles and documents

ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES

The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein A, J, R1, R2, R3, R4, R5, R6, R7, R9, X, m and n are as described herein, compositions thereof, and methods and uses thereof.